beta

ADRO

Aduro BioTech, Inc.

Adro

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Market Cap: 95 Million

Primary Exchange: NASDAQ

Website: http://www.aduro.com

Shares Outstanding: 80.5 Million

Float: 49.9 Million

Dividend: (%)

Beta: 1.02611705041961

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Animal testing

Longest drawdown: 1697 trading days

From: 2015-04-20 To: 2019-12-12

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud